The Ashburn, Va.-based specialty pharmaceutical company, which develops therapeutic products for rare and orphan diseases, said the offering would put up for sale 24.8 million ordinary shares represented by 5 million American Depositary Shares at a purchase price of $1.00 per ADS, as well as pre-funded warrants to purchase 10.3 million ordinary shares represented by 2.1 million ADSs at a pre-funded warrant price of $0.9999 per ADS.
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.